Ticker: PULM

Pulmatrix, Inc. (NASDAQ: PULM) is a biopharmaceutical company focused on developing inhaled therapeutic products for migraine and respiratory diseases using its patented iSPERSE™ technology. As of June 30, 2025, the company reported several key financial metrics. Revenues: No revenue reported fo...

Pulmatrix, Inc. (NASDAQ: PULM) is currently navigating significant financial challenges and strategic changes as it reported its latest quarterly results for the period ending March 31, 2025. Key Highlights: Revenues: The company reported zero revenues for Q1 2025, down from $5.9 million in Q1 2...